James B. Tananbaum

James B. Tananbaum is a declared insider at 5 companies (board member); the most frequent names are Alumis Inc., Kinnate Biopharma Inc. and Latigo Biotherapeutics, Inc. We count 32 filings; the first trade dates from 3 December 2020 and the latest from 10 August 2026.

On the market, this insider has only ever bought: 11 purchases, €28.1M in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 2 share grants. So far in 2026, the count stands at 2 purchases and no sales.

In size, the median ticket on the buying side is €2.1M. On 10 out of 11 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 10 August 2026 with a transaction in Latigo Biotherapeutics, Inc. The clock since the last published purchase (10 August 2026) now reads 72 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.